The efficacy and safety of novel anti-obesity therapies
Journal Title: Αρχεία Ελληνικής Ιατρικής - Year 2015, Vol 32, Issue 3
Abstract
Obesity is a chronic disease with a high prevalence in both developed and developing countries. Lifestyle interventions, such as restricting calorie consumption and increasing physical activity, continue to be the cornerstone of weight-reduction programs. Novel anti-obesity drug therapies are currently gaining in importance. These include lorcaserin (a selective serotonin agonist), phentermine/topiramate combination, naltrexone/bupropion combination (acting on the hypothalamus), and liraglutide, an established anti-diabetic agent which suppresses the appetite. This is a brief review of the evidence on the role of these anti-obesity drugs in the management of obesity.
Authors and Affiliations
A. PAPAZAFIROPOULOU, N. PAPANAS
Keywords
Related Articles
- EP ID EP142868
- DOI -
- Views 88
- Downloads 0
Η θεραπεία της σκλήρυνσης κατά πλάκας<br />
Prevention of cardiovascular diseases. Alma-Ata 1978 and today. <br /> What has been achieved and what should be expected?
A review of the world situation and the events of the preceding 20 years, along with the socioeconomic conditions prevailing world-wide in the late 1970s, led WHO officials to the decision to call an international meetin...
Adrenal insufficiency
No abstract available
Εκτίμηση της θυρεοειδικής λειτουργίας<br /> σε χρόνια αιμοκαθαιρόμενους ασθενείς ηλικίας >50 ετών
ΣΚΟΠΟΣ Οι διαταραχές της θυρεοειδικής λειτουργίας είναι συχνές στους χρόνια αιμοκαθαιρόμενους (ΑΜΚ) ασθενείς, συνήθως είναι ήπιες και ασυμπτωματικές, ενώ η συχνότητά τους αυξάνει προϊούσης της ηλικίας. Σκοπός της εργασία...
The pathogenesis of sepsis syndrome and the role of immunomodulation
Despite important advances in critical care medicine the mortality rate of sepsis syndrome remains high. Sepsis is an inflammatory response of the immune system to bacterial infection. The clinical course of sepsis syndr...